For some patients with chemotherapy-refractory gastric cancer with mismatch repair deficiency or microsatellite instability (MSI), the overall survival rate was also greatly improved after anti-PD-1/PD-L1 immunotherapy. The gene discussed is CD274; the disease is gastric cancer.